Venus Remedies Limited has secured renewal of in-house Research & Development recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D unit, Venus Medicine Research Centre (VMRC).
The DSIR recognition is granted to organizations that operate a dedicated in-house R&D unit with defined research objectives, qualified scientific staff, and separately accounted R&D expenditure. The renewal confirms that VMRC continues to meet these conditions.
The recognition supports VMRC's ongoing work in antimicrobial resistance, including:
- Development of VRP-034, a novel polymyxin B formulation that holds USFDA Qualified Infectious Disease Product (QIDP) designation
- The GASAR resistance surveillance study
The announcement was made through an exchange filing dated June 4, 2026, and signed by Neha, Company Secretary of Venus Remedies Limited.